Cargando…
Cellular and molecular features related to exceptional therapy response and extreme long‐term survival in glioblastoma
Glioblastoma Multiforme (GBM) remains the most common malignant primary brain tumor with a dismal prognosis that rarely exceeds beyond 2 years despite extensive therapy, which consists of maximal safe surgical resection, radiotherapy, and/or chemotherapy. Recently, it has become clear that GBM is no...
Autores principales: | Decraene, B., Vanmechelen, M., Clement, P., Daisne, J. F., Vanden Bempt, I., Sciot, R., Garg, A. D., Agostinis, P., De Smet, F., De Vleeschouwer, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242322/ https://www.ncbi.nlm.nih.gov/pubmed/36776000 http://dx.doi.org/10.1002/cam4.5681 |
Ejemplares similares
-
Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
por: Decraene, Brecht, et al.
Publicado: (2022) -
Publisher Correction: Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
por: Decraene, Brecht, et al.
Publicado: (2022) -
Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma
por: Finotto, Lise, et al.
Publicado: (2023) -
RARE-56. PERITONEAL SEEDING OF A DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR IN A CHILD
por: Messiaen, Julie, et al.
Publicado: (2020) -
OTHR-38. The development of patient-derived models of pediatric brain tumors
por: Messiaen, Julie, et al.
Publicado: (2022)